<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665782</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00004300</org_study_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU-97307</secondary_id>
    <nct_id>NCT00665782</nct_id>
  </id_info>
  <brief_title>Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast</brief_title>
  <official_title>Stress Measures in Women With Newly Diagnosed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about how patients respond to stress and measuring stress&#xD;
      levels in women with newly diagnosed breast cancer may help doctors provide better methods of&#xD;
      treatment and on-going care.&#xD;
&#xD;
      PURPOSE: This research study is measuring stress in women with newly diagnosed stage I, stage&#xD;
      II, or stage III breast cancer or ductal carcinoma in situ of the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Describe the distributions of physiologic, psychosocial, and behavioral response to&#xD;
           stress in women with newly diagnosed breast cancer.&#xD;
&#xD;
        -  Describe the patterns of diurnal cortisol rhythms in women newly diagnosed with breast&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine if diurnal salivary cortisol (mean or pattern) is consistent over two days&#xD;
           within two weeks of study entry.&#xD;
&#xD;
        -  Assess the changes in diurnal cortisol rhythm pattern and night-time urinary epinephrine&#xD;
           excretion change after an intervening stress event (pre- to post-surgery).&#xD;
&#xD;
        -  Determine if the diurnal cortisol rhythm and the night-time urinary excretion correlate&#xD;
           with a variety of self-reported psychosocial factors: optimism (LOT-R), state and trait&#xD;
           anxiety (STAI form Y-2), positive and negative affect (PANAS), depressive symptoms&#xD;
           (CES-D), coping (Brief COPE), and perceived stress (PSS-10).&#xD;
&#xD;
        -  Determine if the diurnal cortisol rhythm and the night-time urinary epinephrine&#xD;
           excretion correlate with socioeconomic stress and discrimination (functional social&#xD;
           support and discrimination [EOD]).&#xD;
&#xD;
        -  Determine if the diurnal cortisol rhythm and the night-time urinary epinephrine&#xD;
           excretion correlate with one lifestyle behavior and dietary fat consumption (Block food&#xD;
           screener).&#xD;
&#xD;
      OUTLINE: Patients are stratified according to race (Caucasian vs African American).&#xD;
&#xD;
      Patients are instructed to collect saliva and urine samples on 2 separate days, within 2&#xD;
      weeks of study enrollment. Saliva samples are collected 6 times a day at baseline, before&#xD;
      breast cancer surgery, and 7-10 days after surgery. Urine samples are collected after&#xD;
      midnight until and including the first morning sample on the saliva-collection days.&#xD;
&#xD;
      Patients also complete questionnaires (either by telephone interview or in person) within 2&#xD;
      weeks of study enrollment and 7-10 days after breast surgery. Stress measures examined&#xD;
      include optimism (LOT-R), trait-anxiety scale (STAI form Y-2), functional social support,&#xD;
      affect and depression (PANAS and CES-D), perceived stress (PSS-10), economic hardship scales,&#xD;
      discrimination (EOD), coping mechanisms (Brief COPE), and dietary fat consumption (Block&#xD;
      Sugar/Fat/Fruit/Vegetable screener).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diurnal cortisol rhythm</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consistency of diurnal salivary cortisol levels over two days</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diurnal cortisol rhythm pattern and night-time urinary epinephrine excretion pre- to post-surgery</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the diurnal cortisol rhythm and the night-time urinary excretion with the measures of psychosocial and behavioral stress responses</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Anxiety Disorder</condition>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study of socioeconomic and demographic variables</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Those diagnosed with stage I-III invasive breast cancer or ductal carcinoma in situ of the&#xD;
        breast within the past 2 weeks&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with stage I-III invasive breast cancer or ductal carcinoma in situ of the&#xD;
             breast within the past 2 weeks&#xD;
&#xD;
          -  Surgery for breast cancer planned&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Able to refrain from:&#xD;
&#xD;
               -  Smoking cigarettes for the 24-hour period of saliva-sample collection&#xD;
&#xD;
               -  Brushing teeth or eating for up to one hour prior to saliva collection&#xD;
&#xD;
          -  More than 1 year since prior therapy for another malignancy&#xD;
&#xD;
          -  At least 1 month since prior withdrawal from hormone-replacement product&#xD;
&#xD;
          -  Able to refrain from steroid inhalers for greater than 24 hours&#xD;
&#xD;
          -  No chronic oral steroids&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia A. Lawrence</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anxiety disorder</keyword>
  <keyword>depression</keyword>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

